The Current State of Diversity in Clinical Trials (DICT)
The DICT Research Initiative’s extensive research findings provide comprehensive insights into the current landscape surrounding Diversity in Clinical Trials. The research sheds light on the challenges, opportunities, and ongoing initiatives within the industry.
Read on for a summary of insights and to download the full report.
DICT Initiative Research Findings
From the varying levels of preparedness among organizations to the obstacles hindering execution, and the adoption of technology tools for improvement, the DICT Initiative research provides a nuanced understanding of the current state of diversity in clinical trials.
The Preparedness Gap
Only one-third feel their organizations are “well” or “very well” prepared to execute diversity plans.
Cost and Capacity Constraints
Over half cite cost constraints and 42% cite a lack of internal capabilities or capacity as significant hindrances.
Top Obstacles Hindering Sites
The biggest hurdles for sites include a lack of time/resources to dedicate to the additional efforts required for DICT (53%) and limited access to underrepresented populations in the area (50%).
Top Obstacles Hindering Sponsors
The biggest hurdles for sponsors include a lack of patient buy-in (50%), traditional mindsets (47%), a lack of sufficient resources (42%), and trial efficiency concerns (38%).
Download the Full DICT Report
Moving from problem identification to execution is crucial when moving forward with diversity plans. With FDA guidelines mandating Diversity Action Plans for Phase 3 studies, there is a pressing need for comprehensive solutions to address diversity obstacles and improve patient representation in clinical trials. Medidata is positioned as a leader in this space, providing solutions to overcome barriers and promote inclusivity in clinical research.
Fill out the form to read the full Diversity in Clinical Trials report.